Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Hospitalier Universitaire de Nīmes
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient must have given their free and informed consent and signed the consent form
The patient must be a member or beneficiary of a health insurance plan
The patient has an WHO score ≤ 3
The patient's estimated life expectancy is more than 3 months.
Patient with histologically proven diagnosis of glioblastoma.
Patient presenting with tumor progression on morphological MRI confirmed by a multidisciplinary committee.
Patient with a unilateral supratentorial target lesion upon inclusion to establish a tumor region of interest (ROI) zone and an equivalent ROI zone in contralateral healthy tissue.
Patient progressing after radiotherapy and at least one line of chemotherapy with TEMODAL
Patient in whom treatment with Bevacizumab monotherapy has been validated by a multidisciplinary committee.
You may not be if
The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study
The subject refuses to sign the consent
It is impossible to give the subject informed information
The patient is under safeguard of justice or state guardianship
Pregnant or breast feeding patients
Hypersensitivity to iodinated contrast media and creatinine clearance less than 60 ml / minute.
